| Literature DB >> 31660878 |
Elham Ahmadi1, Mohammad Khojasteh2, Seyed Mohammad Mortazavi2, Fatemeh Khan-Mohammadi3, Ali Kazemnia4, Javad Beheshtipour5, Mahdieh Raeeszadeh6.
Abstract
BACKGROUND: Several reports designate the recent increase in community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) nasal carriage. Because of the scanty information regarding the nasal carriage sate of MRSA in the west of Iran, the purpose of the present study was to determine the frequency of CA-MRSA in Sanandaj city.Entities:
Keywords: Antibiogram; CA-MRSA; Iran; Pvl; SCCmec
Year: 2019 PMID: 31660878 PMCID: PMC6819401 DOI: 10.1186/s12879-019-4567-1
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Age group and sex characteristics, and distribution of SANC and MRSA
| Age | Female volunteers ( | SANC ( | MRSA ( | Male volunteers ( | SANC ( | MRSA ( |
|---|---|---|---|---|---|---|
| 1–10 | 31 | 12 | 3 | 45 | 22 | 7 |
| > 10–20 | 27 | 11 | 4 | 39 | 27 | 12 |
| > 20–30 | 34 | 7 | 1 | 42 | 13 | 3 |
| > 30–40 | 67 | 3 | 1 | 52 | 9 | 3 |
| > 40–50 | 58 | 6 | 2 | 54 | 12 | 6 |
| > 50–60 | 33 | 14 | 1 | 46 | 18 | 9 |
| > 60–70 | 28 | 15 | 1 | 44 | 12 | 2 |
Bivariate analysis of demographic information and risk factors for MRSA
| Factor | SANC Frequency (% column) | MRSA |
| Crude OR | 95% CI | |
|---|---|---|---|---|---|---|
| Positive No. (%) | Negative No. (%) | |||||
| Sex | ||||||
| Male | 113 (35.09) | 42 (37.17) | 71 (62.83) | 0.001 | 6.48 | 2.13–19.66 |
| Female | 68 (24.46) | 13 (19.12) | 55 (80.88) | |||
| Agea | ||||||
| 1–10 years | 34 (44.74) | 10 (29.41) | 24 (70.59) | – | 1 | – |
| 10–20 years | 38 (57.58) | 16 (42.10) | 22 (57.90) | 0.002 | 10.64 | 2.37–47.79 |
| 20–30 years | 20 (26.32) | 4 (20.00) | 16 (80.00) | 0.78 | 1.33 | 0.17–10.52 |
| 30–40 years | 12 (10.08) | 4 (33.33) | 8 (66.77) | 0.48 | 2.18 | 0.25–19.29 |
| 40–50 years | 18 (16.07) | 8 (44.44) | 10 (55.56) | 0.05 | 8.85 | 1.02–76.89 |
| 50–60 years | 32 (40.51) | 10 (31.25) | 22 (68.75) | 0.08 | 4.62 | 0.83–25.53 |
| 60–70 years | 27 (37.50) | 3 (11.11) | 24 (88.99) | 0.19 | 0.12 | 0.004–3.03 |
| Hospital visit in the last 3 months | ||||||
| Yes | 58 (32.77) | 20 (34.48) | 38 (65.51) | 0.09 | 2.96 | 0.85–10.36 |
| No | 123 (29.08) | 35 (28.45) | 88 (71.54) | |||
| Chronic renal disorder | ||||||
| Yes | 27 (39.71) | 11 (40.74) | 16 (59.25) | 0.91 | 1.14 | 0.14–9.01 |
| No | 154 (28.95) | 44 (28.57) | 110 (71.42) | |||
| Smoking habitsa | ||||||
| Ex-smoker | 22 (44.90) | 4 (18.18) | 18 (81.81) | – | 1 | – |
| Current smoker | 39 (31.97) | 16 (41.02) | 23 (58.97) | 0.09 | 12.96 | 0.64–263.94 |
| Non-smoker | 120 (27.97) | 35 (29.16) | 85 (70.83) | 0.23 | 6.4 | 0.3–136.99 |
| Occupation | ||||||
| Yes | 97 (35.93) | 22 (22.68) | 75 (77.31) | 0.04 | 1.32 | 1.24–3.52 |
| No | 84 (25.45) | 33 (39.28) | 51 (60.71) | |||
| Household members who have a profession in hospital care | ||||||
| Yes | 36 (47.37) | 16 (44.44) | 20 (55.55) | 0.003 | 13.07 | 2.44–70.11 |
| No | 145 (80.11) | 39 (26.89) | 106 (73.10) | |||
| Skin and soft tissue infection in the last 12 months | ||||||
| Yes | 14 (36.84) | 9 (64.28) | 5 (35.71) | 0.02 | 46.57 | 2.03–1068.89 |
| No | 167 (29.72) | 46 (27.54) | 121 (72.45) | |||
| Allergy | ||||||
| Yes | 15 (22.39) | 3 (20.00) | 12 (80.00) | 0.06 | 0.1 | 0.01–0.82 |
| No | 166 (31.14) | 52 (11.32) | 114 (88.68) | |||
| Diabetes mellitus | ||||||
| Yes | 7 (36.84) | 1 (14.28) | 6 (85.71) | 0.9 | 0.04 | 0.001–1.62 |
| No | 174 (29.95) | 54 (31.03) | 20 (68.96) | |||
| Surgery in the last 12 months | ||||||
| Yes | 4 (26.67) | 1 (25.00) | 3 (75.00) | 0.82 | 0.65 | 0.02–25.57 |
| No | 177 (30.26) | 54 (30.50) | 123 (69.49) | |||
| Chronic liver disorder | ||||||
| Yes | 0 (0.00) | 0 (0.00) | 0 (0.00) | 1 | – | – |
| No | 181 (30.37) | 55 (30.38) | 126 (69.61) | |||
| Use of steroids | ||||||
| Yes | 3 (25.0) | 1 (33.33) | 2 (66.66) | 0.22 | 13.95 | 0.21–912.44 |
| No | 178 (30.27) | 54 (30.38) | 124 (69.66) | |||
| Oral contraceptive | ||||||
| Yes | 8 (21.62) | 3 (37.5) | 5 (62.5) | 0.31 | 4.61 | 0.24–89.79 |
| No | 173 (30.73) | 52 (30.05) | 121 (69.94) | |||
| Alcoholism | ||||||
| Yes | 7 (41.18) | 3 (42.85) | 4 (57.14) | 0.388 | 4.04 | 0.176–92.58 |
| No | 174 (29.58) | 52 (29.88) | 122 (70.11) | |||
a Regression was used with the first value within variable acting as reference value
Variables entered: sex (male versus female), and the other variables, yes versus no.
OR: Odds ratio
CI: Confidence interval
Multiple logistic regression analysis of demographic information and risk factors associated with MRSA
| Risk factors |
| Adjusted OR | 95% CI |
|---|---|---|---|
| Sex | 0.001 | 3.86 | 1.70–8.76 |
| Age | 0.038 | 0.92 | 0.78–1.10 |
| Skin and soft tissue infection in the last 12 months | 0.03 | 4.70 | 1.22–18.18 |
| Occupation | 0.001 | 0.22 | 0.09–0.51 |
| Household members who have a profession in hospital care | 0.002 | 5.24 | 1.86–14.76 |
OR: Odds ratio
CI: Confidence interval
Frequency of SCCmec type IV subtypes among MRSA isolates
| Subtype | Female | Male | Total |
|---|---|---|---|
| IVa | 3 (5.45%) | 15 (27.27%) | 18 (32.72%) * |
| IVb | 0 (0%) | 4 (7.27%) | 4 (4.27%) * |
| IVc | 2 (3.63%) | 11 (20%) | 13 (23.63%) * |
| IVd | 1 (1.81%) | 0 (0%) | 1 (1.81%) |
| IVh | 3 (5.45%) | 5 (9.09%) | 8 (14.54%) * |
| Total | 9 (16.36%) | 35 (63.63%) | 44 (80%) |
* Strains harbored pvl included 3 isolates in each IVa and IVc subtypes and 1 isolate in each IVb and IVh subtype
Antibiotic resistance profile of S. aureus isolated from nasal carriers in Sanandaj city
| Antibiotic |
| MRSA | ||||
|---|---|---|---|---|---|---|
| R | I | S | R | I | S | |
| Rifampin | 15 (8.28%) | 8 (4.41%) | 158 (87.29%) | 3 (5.45%) | 1 (1.81%) | 51 (92.72%) |
| Tetracyclin | 33 (18.23%) | 0 (0%) | 148 (81.76%) | 13 (23.63%) | 0 (0%) | 42 (76.36%) |
| Chloramphenicol | 39 (21.54%) | 6 (3.31%) | 136 (75.13%) | 8 (14.54%) | 1 (1.81%) | 46 (83.63%) |
| Fusidic acid | 6 (3.31%) | 0 (0%) | 175 (96.68%) | 1 (1.81%) | 0 (0%) | 54 (98.18%) |
| Trimethoprim-sulphamethoxazole | 17 (9.39%) | 2 (1.10%) | 162 (89.50%) | 4 (7.27%) | 0 (0%) | 51 (92.72%) |
| Clindamycin | 142 (78.45%) | 9 (4.97%) | 30 (16.57%) | 32 (58.18%) | 4 (7.27%) | 19 (34.54%) |
| Gentamicin | 4 (2.20%) | 2 (1.10%) | 175 (96.68%) | 1 (1.81%) | 0 (0%) | 54 (98.18%) |
| Erythromycin | 92 (50.82%) | 16 (8.83%) | 73 (40.33%) | 27 (49.09%) | 2 (3.63%) | 26 (47.27%) |
| Penicillin | 173 (95.58%) | 0 (0%) | 8 (4.41%) | 55 (100%) | 0 (0%) | 0 (0%) |
| Vancomycin | 21 (11.60%) | 9 (4.97%) | 151 (83.42%) | 6 (10.90%) | 3 (3.63%) | 46 (83.63%) |
| Mupirocin | 3 (1.65%) | 1 (0.55%) | 177 (97.79%) | 0 (0%) | 1 (1.81%) | 54 (98.18%) |
| Ciprofloxacin | 87 (48.06%) | 11 (6.07%) | 83 (45.85%) | 16 (29.09%) | 3 (3.63%) | 36 (65.45%) |
R: resistant; I: intermediate; S: sensitive; n: number